Hydrogel device for analgesic drugs with in-situ loading and polymerization
- PMID: 37451545
- DOI: 10.1016/j.jconrel.2023.07.022
Hydrogel device for analgesic drugs with in-situ loading and polymerization
Abstract
The high prevalence of opioid addiction and the shortcomings of systemic opioids has increased the pace of the search for alternative methods of pain management. The local delivery of pain medications has started to be used as a tool for pain management and to decrease the use of systemic opioids for these patients. Here, we explored an in-situ polymerizable hydrogel system for the local delivery of analgesics and nonsteroid anti-inflammatory drugs (NSAID) for orthopaedic applications. We synthesized a series of methacrylated oligomeric polyethylene glycol-co-lactic acid polymer using microwave radiation for the delivery of bupivacaine hydrochloride as an analgesic and ketorolac tromethamine as an NSAID. We determined drug elution and gel degradation profiles in vitro. Biocompatibility was assessed against osteoblasts in vitro and by histological analysis after subcutaneous implantation for 4 weeks in vivo. Intra-articular and systemic concentrations and pharmacokinetic parameters were estimated using a two-compartment pharmacodynamic model based on in-vitro elution profiles. This type of in-situ applicable hydrogels is promising for extending the local efficacy of pain medication and further reducing the need for opioids.
Keywords: Bupivacaine HCl; Ketorolac tromethamine; Local drug delivery; Methacrylated; NSAID; Nanoarchitectonics; Orthopaedics; PEG; PLA.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: OKM: Royalties - Corin, Mako, Iconacy, Renovis, Arthrex, ConforMIS, Meril Healthcare, Exactech, Cambridge Polymer Group; Stake/Equity-Cambridge Polymer Group, Orthopaedic Technology Group, Alchimist. None of these are in direct conflict with the study. EO: Royalties-Corin, Iconacy, Renovis, Arthrex, ConforMIS, Meril Healthcare, Exactech; Paid consultant – WL Gore & Assoc; Editorial Board – JBMR; Officer/Committee- SFB, ISTA. None of these are in direct conflict with the study. MDA: Corlamlabs, None of these are in direct conflict with the study.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources